Journal
VACCINE
Volume 26, Issue 31, Pages 3842-3852Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.05.016
Keywords
henipavirus; subunit vaccine; CpG; mucosal immunity
Categories
Funding
- NIAID NIH HHS [AI057168, U01 AI077995, U54 AI057168] Funding Source: Medline
Ask authors/readers for more resources
Nipah virus (NiV) and Hendra virus (HeV) are closely related deadly zoonotic paramyxoviruses that have emerged and re-emerged over the last 10 years. In this study, a subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein from HeV (sG(HeV)) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Different amounts of sG(HeV) were employed and sG-induced immunity was examined. Vaccinated animals demonstrated varying levels of NiV-specific Ig systemically and importantly, all vaccinated cats possessed antigen-specific IgA on the mucosa. Upon oronasal challenge with NiV (50,000 TCID50), all vaccinated animals were protected from disease although virus was detected on day 21 post-challenge in one animal. The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses. (C) 2008 CSIRO. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available